Endometriosis - Epidemiology Forecast to 2030

Endometriosis is a common gynecological condition affecting women of reproductive ages. Women with endometriosis develop tissue that looks and acts like endometrial tissue outside of the uterus, usually on other reproductive organs inside the abdominal cavity (Hopkins Medicine, 2021; Royal College of Nursing, 2021). Endometriosis has three well-recognized phenotypes: superficial peritoneal lesions (SUP), ovarian endometriomas (OMA) and deep infiltrating endometriosis (DIE) (Chapron et al., 2019). The disease is further stratified by the American Society for Reproductive Medicine (ASRM) classification into four stages, I, II, III and IV (Canis et al., 1997). The clinical presentation includes chronic pelvic pain, dysmenorrhea, dyspareunia, dyschezia, intermenstrual bleeding, and difficulty in getting pregnant.

This report provides an overview of the risk factors, comorbidities, and the global and historical epidemiological trends for endometriosis in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan). The report includes a 10-year epidemiology forecast for the diagnosed prevalent cases of endometriosis. The diagnosed prevalent cases of endometriosis are segmented by age (12–54 years) and laparoscopy confirmation status (whether suspected or confirmed endometriosis). The report also includes the diagnosed prevalent cases of endometriosis further segmented by ASRM stage and classified as Stage I (Minimal), Stage II (Mild), Stage III (Moderate), or Stage IV (Severe); phenotype: Superficial Peritoneal Endometriosis (SUP), Ovarian Endometrioma (OMA), and Deep Infiltrating Endometriosis (DIE); cases undergoing laparoscopy; and comorbidities such as chronic pelvic pain (CPP), dysmenorrhea, and dyspareunia. The following data describes epidemiology of endometriosis. In the 7MM, The publisher epidemiologists forecast a decrease in the diagnosed prevalent cases of endometriosis from 3,317,609 cases in 2020 to 3,232,223 cases in 2030, at an AGR of -0.26% over the forecast period. Younger adult women are predominantly affected. These findings are in line with the The publisher estimates and these trends are reflected in the publisher’s forecast for the diagnosed prevalent cases for the 7MM.

Scope

• The Endometriosis Epidemiology Report provides an overview of the risk factors and global trends of Endometriosis in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan).
• The report includes a 10-year epidemiology forecast for the diagnosed prevalent cases of endometriosis. The diagnosed prevalent cases of endometriosis are segmented by age (12–54 years) and laparoscopy confirmation status (whether suspected or confirmed endometriosis). The report also includes the diagnosed prevalent cases of endometriosis further segmented by ASRM stage and classified as Stage I (Minimal), Stage II (Mild), Stage III (Moderate), or Stage IV (Severe); phenotype: Superficial Peritoneal Endometriosis (SUP), Ovarian Endometrioma (OMA), and Deep Infiltrating Endometriosis (DIE); cases undergoing laparoscopy; and comorbidities such as chronic pelvic pain (CPP), dysmenorrhea, and dyspareunia.
• The endometriosis epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
• The Epidemiology Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.

Reasons to Buy

The Endometriosis Epidemiology series will allow you to:

• Develop business strategies by understanding the trends shaping and driving the global endometriosis market.
• Quantify patient populations in the global endometriosis market to improve product design, pricing, and launch plans.
• Organize sales and marketing efforts by identifying the age groups that present the best opportunities for endometriosis therapeutics in each of the markets covered.
• Understand magnitude of endometriosis population by laparoscopy confirmation status, and comorbidities.